FOLD is now overvalued and could go down -30%

Based on our analysis, Amicus Therapeutics has received an overvalued rating of 1 out of 5 stars from Cashu. This rating is supported by several financial ratios that indicate the company is not performing favorably compared to its sector. One of the key metrics to consider is the Return on Equity (ROE) ratio, which for Amicus stands at -28.91, while the sector average is significantly lower at -74.11. A negative ROE indicates that the company is not generating profit from its shareholders' equity, suggesting inefficiencies in utilizing funds to create value. Additionally, the Return on Assets (ROA) ratio for Amicus is -7.15, compared to the sector's -47.59. A negative ROA signals that the company is not effectively converting its assets into profits, which could raise concerns about its operational effectiveness in generating returns. Moreover, the company's Net Profit Margin is recorded at -10.62, while the sector average shows a worse performance at -134.62. While Amicus has a superior net profit margin, the negative figure still reflects ongoing losses, highlighting the challenges it faces in achieving profitability. These financial indicators collectively suggest that Amicus Therapeutics is not in a favorable position relative to its industry peers. Investors may need to carefully evaluate these metrics before considering any investment in the company. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.